LMLN and leishmaniasis: Some antigens, such as GP63, GP46, LACK, CPB, CPA, A2, PSA-2, HASPB1, LeIF, and LCR1, have been tested like recombinant proteins, synthetic peptides, and/or DNA vaccines against leishmaniasis, but they have induced only partial protection [69]–[71].